Médecine de précision dans l'épilepsie génétique et les encéphalopathies développementales (DEE)
La médecine de précision dans les encéphalopathies neurodéveloppementales et épileptiques (EED) cherche à orienter le traitement pharmacologique vers le mécanisme physiopathologique et moléculaire sous-jacent à la variante génétique du patient, en évitant les thérapies inefficaces ou nocives.
Répartition clinique des approches thérapeutiques représentées
Les principales catégories moléculaires et cibles thérapeutiques représentées dans le tableau sont détaillées ci-dessous :
1. Canalopathies sodiques et potassiques
- SCN1A (Syndrome de Dravet – Perte de fonction) : Approche de précision avec fenfluramine, cannabidiol, Stiripentol, clobazam et valproate. Alerte de précision : Les bloqueurs des canaux sodiques (carbamazépine, phénytoïne, lamotrigine) sont formellement contre-indiqués en raison du risque d'aggravation sévère et de convulsions réfractaires.
- SCN2A et SCN8A (variantes de gain de fonction au début) : Indication préférentielle de bloqueurs des canaux sodiques à fortes doses (phénytoïne, carbamazépine), qui rétablissent l'hyperexcitabilité membranaire.
- KCNQ2 / KCNQ3 (canaux potassiques Kv7.2/Kv7.3) : Ouverture sélective des chaînes K+ via rétigabine (ézogabine) et une réponse favorable aux bloqueurs de sodium tels que la carbamazépine dans les phases précoces.
- KCNT1 (canaux potassiques Na+-dépendants) : Utilisation de quinidine comme modulateur spécifique hors AMM dans les épilepsies focales réfractaires des enfants migrants.
2. Troubles métaboliques et du transport cérébral
- SLC2A1 (Déficit du transporteur cérébral de glucose GLUT1) : Thérapie de substitution obligatoire Régime cétogène tôt, fournissant des corps cétoniques comme substrat énergétique cérébral alternatif au glucose.
- ALDH7A1 / PNPO (épilepsies dépendantes de la pyridoxine) : Complémentation spécifique tout au long de la vie avec pyridoxine (vitamine B6) o pyridoxal 5′-phosphate (PLP).
3. mTORopathies et voies de prolifération/signalisation
- TSC1/TSC2 (complexe de sclérose tubéreuse) et DEPDC5/NPRL2/NPRL3 (complexe GATOR1) : Hyperactivation de la cascade intracellulaire mTOR. Approche ciblée avec Inhibiteurs de mTOR (Everolimus, Sirolimus) pour le contrôle des convulsions et des dysplasies corticales focales associées.
4. Modulateurs des récepteurs et voies synaptiques
- GRIN2A / GRIN2B (sous-unités du récepteur NMDA) : Modulation allostérique et blocage des récepteurs NMDA par mémantine dans des variantes avec gain de fonction.
- PCDH19 (Protocadhérine 19) : Thérapies modulatrices des neurostéroïdes (ganaxolone) et des protocoles hormonaux spécifiques.
Littérature
19955111
{19955111:6YYVTK6C}
1
Vancouver
50
défaut
7473
https://neuropediatoolkit.org/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%226YYVTK6C%22%2C%22library%22%3A%7B%22id%22%3A19955111%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Beltr%5Cu00e1n-Corbellini%20et%20al.%22%2C%22parsedDate%22%3A%222022-02-17%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BBeltr%26%23xE1%3Bn-Corbellini%20%26%23xC1%3B%2C%20Aledo-Serrano%20%26%23xC1%3B%2C%20M%26%23xF8%3Bller%20RS%2C%20P%26%23xE9%3Brez-Palma%20E%2C%20Garc%26%23xED%3Ba-Morales%20I%2C%20Toledano%20R%2C%20et%20al.%20Epilepsy%20Genetics%20and%20Precision%20Medicine%20in%20Adults%3A%20A%20New%20Landscape%20for%20Developmental%20and%20Epileptic%20Encephalopathies.%20Front%20Neurol%20%5BInternet%5D.%202022%20Feb%2017%20%5Bcited%202026%20June%2015%5D%3B13.%20Available%20from%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-ItemURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fwww.frontiersin.org%5C%2Fjournals%5C%2Fneurology%5C%2Farticles%5C%2F10.3389%5C%2Ffneur.2022.777115%5C%2Ffull%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fwww.frontiersin.org%5C%2Fjournals%5C%2Fneurology%5C%2Farticles%5C%2F10.3389%5C%2Ffneur.2022.777115%5C%2Ffull%26lt%3B%5C%2Fa%26gt%3B%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Epilepsy%20Genetics%20and%20Precision%20Medicine%20in%20Adults%3A%20A%20New%20Landscape%20for%20Developmental%20and%20Epileptic%20Encephalopathies%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%5Cu00c1lvaro%22%2C%22lastName%22%3A%22Beltr%5Cu00e1n-Corbellini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%5Cu00c1ngel%22%2C%22lastName%22%3A%22Aledo-Serrano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rikke%20S.%22%2C%22lastName%22%3A%22M%5Cu00f8ller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eduardo%22%2C%22lastName%22%3A%22P%5Cu00e9rez-Palma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Irene%22%2C%22lastName%22%3A%22Garc%5Cu00eda-Morales%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rafael%22%2C%22lastName%22%3A%22Toledano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antonio%22%2C%22lastName%22%3A%22Gil-Nagel%22%7D%5D%2C%22abstractNote%22%3A%22This%20review%20aims%20to%20provide%20an%20updated%20perspective%20of%20epilepsy%20genetics%20and%20precision%20medicine%20in%20adult%20patients%2C%20with%20special%20focus%20on%20developmental%20and%20epileptic%20encephalopathies%20%28DEEs%29%2C%20covering%20relevant%20and%20controversial%20issues%2C%20such%20as%20defining%20candidates%20for%20genetic%20testing%2C%20which%20genetic%20tests%20to%20request%20and%20how%20to%20interpret%20them.%20A%20literature%20review%20was%20conducted%2C%20including%20findings%20in%20the%20discussion%20and%20recommendations.%20DEEs%20are%20wide%20and%20phenotypically%20heterogeneous%20electroclinical%20syndromes.%20They%20generally%20have%20a%20pediatric%20presentation%2C%20but%20patients%20frequently%20reach%20adulthood%20still%20undiagnosed.%20Identifying%20the%20etiology%20is%20essential%2C%20because%20there%20lies%20the%20key%20for%20precision%20medicine.%20Phenotypes%20modify%20according%20to%20age%2C%20and%20although%20deep%20phenotyping%20has%20allowed%20to%20outline%20certain%20entities%2C%20genotype-phenotype%20correlations%20are%20still%20poor%2C%20commonly%20leading%20to%20long-lasting%20diagnostic%20odysseys%20and%20ineffective%20therapies.%20Recent%20adult%20series%20show%20that%20the%20target%20patients%20to%20be%20identified%20for%20genetic%20testing%20are%20those%20with%20epilepsy%20and%20different%20risk%20factors.%20The%20clinician%20should%20take%20active%20part%20in%20the%20assessment%20of%20the%20pathogenicity%20of%20the%20variants%20detected%2C%20especially%20concerning%20variants%20of%20uncertain%20significance.%20An%20accurate%20diagnosis%20implies%20precision%20medicine%2C%20meaning%20genetic%20counselling%2C%20prognosis%2C%20possible%20future%20therapies%2C%20and%20a%20reduction%20of%20iatrogeny.%20Up%20to%20date%2C%20there%20are%20a%20few%20tens%20of%20gene%20mutations%20with%20additional%20concrete%20treatments%2C%20including%20those%20with%20restrictive%5C%2Fsubstitutive%20therapies%2C%20those%20with%20therapies%20modifying%20signaling%20pathways%2C%20and%20channelopathies%2C%20that%20are%20worth%20to%20be%20assessed%20in%20adults.%20Further%20research%20is%20needed%20regarding%20phenotyping%20of%20adult%20syndromes%2C%20early%20diagnosis%2C%20and%20the%20development%20of%20targeted%20therapies.%22%2C%22date%22%3A%222022-02-17%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.3389%5C%2Ffneur.2022.777115%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.frontiersin.org%5C%2Fjournals%5C%2Fneurology%5C%2Farticles%5C%2F10.3389%5C%2Ffneur.2022.777115%5C%2Ffull%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221664-2295%22%2C%22language%22%3A%22English%22%2C%22collections%22%3A%5B%22LHRY9URB%22%5D%2C%22dateModified%22%3A%222026-06-15T16%3A09%3A49Z%22%7D%7D%5D%7D
1.
Beltrán-Corbellini Á, Aledo-Serrano Á, Møller RS, Pérez-Palma E, García-Morales I, Toledano R, et al. Génétique de l'épilepsie et médecine de précision chez les adultes : un nouveau paysage pour les encéphalopathies développementales et épileptiques. Front Neurol [Internet]. 17 février 2022 [cité le 15 juin 2026] ;13. Disponible à partir de : https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2022.777115/full